Recent Updates
Recently added Catalysts
DCTH Positive Sentiment

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Key Takeaway: Delcath Systems, Inc. announced the granting of equity awards under Nasdaq Rule 5635(c)(4). The awards, totaling 21,200 Restricted Stock Units (RSUs), were approved by the Compensation Committee. These inducements were given to three individuals with grant dates in September and October 2026.

Market Sentiment Analysis

POSITIVE FACTORS

  • Delcath granted equity awards to three individuals.
  • The grants were approved by the Compensation Committee.
  • The awards are part of a strategic inducement plan.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+111%
120-day peak, hindsight
Typical move
26.5%
average across 3 past catalysts
Lead asset
Hepzato Kit (melphalan HDS)
Phase 2 · Refractory Metastatic Colorectal Cancer

Full Press Release Details

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company’s Compensation Committee, as material inducements to three individuals whose grant date was in either September 2026 or October 2026. The grants, in the form of Restricted Stock Units (RSUs), totaled 21,2

Frequently Asked Questions

What did Delcath announce?

Delcath announced inducement equity grants approved by its Compensation Committee.

How many RSUs were granted?

The article states the total was 21,2 but cuts off before the unit.

Who received the grants?

Three individuals received the grants as material inducements.

When are the grants dated?

Grant dates fall in September or October 2026.

Last updated: Nov 17, 2026